← Back to headlines
Pfizer's Ibrance Receives FDA Label Expansion for Breast Cancer Drug
Pfizer has been granted an FDA label expansion for its breast cancer drug, Ibrance.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Supreme Court Allows Trump's White House Ballroom Construction to Proceed
27m ago
US Army Secretary Driscoll Resigns Following Friction With Hegseth
29m ago
EU Halts Brazilian Meat Imports Over Antibiotic Safety Concerns
38m ago
Woman Shot Dead by Police After Stabbing Two in New York’s Times Square
46m ago